Zum Seiteninhalt springen

Dr. Oliver Klein:
"When Virchow Meets Mass Spectrometry-how Molecular Signatures May Aid Predict Disease Progression and Therapy Outcome"

Intra-tissue heterogeneity and its evolution over disease course have assisted an expansion of tissue sample collection accompanying patient treatment and trials worldwide. In-depth analysis and further interpretation with respect to potential clinical implications will achieve a better grasp of the extent of intra tissue heterogeneity in several disease to improve personalized patient treatment.  In disease progression, in general, is known to be affected by cellular interplay and the surrounding microenvironment. Taken together, there is unmet need for reliable disease risk classification that takes the microenvironment and spatial heterogeneity into account. Mass spectrometry imaging (MSI) innovative technology combines the comprehensive mass spectrometric technique with a conventional histological evaluation. It allows unlabeled as well targeted analysis of molecules (e.g., metabolites, proteins, peptide, lipids and glycans) directly on a single tissue section, preserving their spatial coordinates and generating a molecular intensity map displaying the spatial relative molecule abundance. Consequently, BIH's Mass Spectrometry Imaging unit helps discover biomarkers for therapy stratification and decipher tissue heterogeneities by advancing MSI technology and combining it with machine-learning algorithms.

Dr. Hagen Kulbe:
"In Silico Prediction of Novel Therapeutic Approaches To Distinct Molecular Subtypes of HGSOC"

Tumor heterogeneity in high-grade serous ovarian cancer (HGSOC) is a proposed cause of acquired resistance to treatment and high rates of relapse. The failure to effectively treat the distinct molecular subtypes to lower mortality highlights the need for effective targeted therapeutic strategies for personalized medicine (PM). Here, we integrated in silico, gene expression and in vivo murine patient-derived xenograft (PDX) drug response data to elucidate potential actionable targets within the distinct molecular phenotypes of mesenchymal HGSOC. Our results revealed a complex tumor microenvironment-mediated cytokine signaling network implicating TNF-α, IL-6 and TGF-β in constitutive activation of the PI3K/AKT pathway as a principal driver of mesenchymal HGSOC. The in silico predictions were corroborated by phospho-proteomics data revealing hyperactivation of PIK3CA and PAK4. Accordingly, PI3K inhibition achieved the highest efficacy in PDX models. Thus, our work suggests treatment strategies involving inhibition of PI3K, CK2 and SRC, or PAK4/p38 for the PM of mesenchymal HGSOC.

Speaker: Dr. Oliver Klein (Lead of the BIH Imaging Mass Spectrometry Unit|KleinLab, BIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité (BIH))

Dr. Oliver Klein received hismaster degree in Pharmaceutical/Chemical Engineering at the Beuth University of Applied Sciences and was subsequently focusing on the expression of protein domains to structure elucidation via NMR and mass spectrometry at the Leibniz Institute for Molecular Pharmacology (FMP) Berlin. Since 2007 he is working at the Charité, leading the Proteomics Unit at Berlin-Brandenburg Center for Regenerative Therapies (today BIH Center for Regenerative Therapies) since 2009. Dr. Klein received his PhD in the field of regenerative medicine focusing on patho-physiological processes in the healing process of injured muscles using imaging MS. Today Dr. Oliver Klein leads the “Imaging mass spectrometry Unit @ BIH” and is involved in several clinically driven projects including BMBF (e.g. MSTAR,SOXALS), DFG (SFB 1444, SFB 1340) , EU (Reshape) and industry cooperations (Pfizer, Bruker).

Speaker: Dr. Hagen Kulbe (Department of Gynaecology, Charité Comprehensive Cancer Centre)

After receiving his diploma in Biochemistry at the Freie Universität Berlin, Dr. Hagen Kulbe pursued his PhD at the Max-Delbrück-Center with studies about„Recombinant adenoviral vectors expressing DNA of tumour antigens and IL-12, respectively, for the use as cancer vaccines-preclinical studies”. He then spent several years as a postdoctoral research assistant at the Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary, University of London. Since 2014 he is a senior scientist at the Department of Gynaecology, Charité Comprehensive Cancer Centre, Charité Medical University Berlin.

Chair: Dr. Michael Schmueck-Henneresse (Group Leader, BIH Center for Regenerative Therapies (BCRT), BeCAT and Charité, Experimental Immunotherapy Group)

Dr. Michael Schmueck-Henneresse is a biotechnologist and PI at the BIH Center for Regenerative Therapies. His post-graduate scientific training is in adaptive and onco-immunology at the Charité and at Baylor College of Medicine Houston. Over the past 14 years, his research has focused on understanding the basic processes that control T cell migration and activation in autoimmunity, transplantation and cancer. His research focuses on how T cells coordinate an effective immune memory against virus-infected or malignant cells and how this can be specifically attenuated in autoimmune diseases or after organ transplantation. To this end, he is developing technologies that can detect, characterize and genetically reprogram T cell specificity, as well as strategies to optimize the quality of T cells for therapeutic purposes. His goal is to develop diagnostic tools to predict the immune response, as well as to provide new treatment options by developing appropriate T cell products.


The Lecture will be held online via GoToMeeting. To participate in the Lecture, please register hereThe registration will be open until maximal participant capacity is reached.

Login via GoToMeeting



Thursday, 23 June 2022
3:00 – 4:30 pm


via GoToMeeting
A login-link or dial-in number for the phone as well as an access code for the Lecture will be provided the evening before the event.


Please register here.
The registration will be open until maximal participant capacity is reached.

PD Dr. Mareen Matz

Projektmanagerin Nationale Strategie für gen- und zellbasierte Therapien, Forschungskoordinatorin